Long-term risks from prostate cancer treatment detailed in new report

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer

Androgen receptor alterations consistently emerged in serial liquid biopsies researchers used to track how metastatic prostate cancer evolves under treatment pressure. These alterations were linked to poorer outcomes across therapies, according to a multi-center collaboration of investigators from Sylvester, UC San Diego, Moores Cancer Center, the University of California, San Francisco, Scripps Research Institute, and Guardant Health.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

February 06, 2026

Vol.52 No.05

Clinical Roundup

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

January 30, 2026

Vol.52 No.04

Long-term risks from prostate cancer treatment detailed in new report

YOU MAY BE INTERESTED IN

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds

Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds

Androgen receptor alterations in bloodwork linked to poorer outcomes across therapies treating metastatic prostate cancer

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Renew today!

Subscriber content

Never miss an issue!

Login